Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease.

Deirdre MladsiChristine BarnettKavita Aggarwal Michael VredenburgDouglas DieterichW Ray Kim

Published in: ClinicoEconomics and outcomes research : CEOR (2020)

The use of avatrombopag is expected to be cost-saving while reducing the need for prophylactic platelet transfusions compared with platelet transfusion and lusutrombopag.

Keyphrases

cardiac surgery
combination therapy
acute kidney injury
sickle cell disease
smoking cessation